Month: August 2022

Novaturas group started 2022 with strong sales results. The income generated during the first half of 2022 surpassed both the results for the same period in 2021 and the pre-pandemic results in 2019. The company generated EUR 92M of income during the first half-year of 2022 and served 128K travelers throughout the entire group. However, rapidly increasing aviation fuel prices had a negative impact on profitability figures and therefore the EBITDA was negative and reached EUR 750K. “In order to manage the impact of increased aviation prices, we applied a fuel insurance strategy during the second quarter of this year, which proved to be effective – financial derivatives allowed us to generate EUR 103K of profit. Nevertheless, we did not insure the entire scheduled flight program and the aviation fuel prices continued growing significantly...

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the pricing of an upsized underwritten public offering of 64,285,714 shares of its common stock and accompanying warrants to purchase up to 64,285,714 shares of common stock at a combined public offering price of $0.70 per share and accompanying warrant. The warrants have an exercise price of $0.85 per share, are exercisable immediately, and will expire five years following the date of issuance. The gross proceeds to UNITY from the offering are expected to be approximately $45.0 million, before underwriting discounts and commissions and offering costs. All of the securities are being offered by UNITY. The offering...

— Additional indications: treatment for Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis and pediatric Crohn’s disease SHANGHAI, China, Aug. 17, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the Company has received an Acceptance Notice issued by the National Medical Products Administration (“NMPA”). The supplemental application for additional indications of the company’s adalimumab injection (project code: UBP1211, trade name: 君迈康), including the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children...

PALM BEACH GARDENS, Fla., Aug. 17, 2022 (GLOBE NEWSWIRE) — Dycom Industries, Inc. (NYSE: DY) will host a conference call to discuss fiscal 2023 second quarter results on Wednesday, August 24, 2022, at 9:00 a.m. Eastern time. Dycom will issue a press release reporting its results earlier that morning. Interested parties may participate in the question and answer session of the conference call by registering at https://register.vevent.com/register/BI8912ef4c95fa46e899173079528bf98f. Upon registration, participants will receive a dial-in number and unique PIN to access the call. Participants are encouraged to join approximately ten minutes prior to the scheduled start time. For all other attendees, a live listen-only audio webcast of the call, including an accompanying slide presentation, can be accessed directly at https://edge.media-server.com/mmc/p/nkn4jebu....